Aspect Biosystems
PlatformVancouver, British Columbia, CanadaFounded 2013
Aspect Biosystems develops bioprinted tissue therapeutics using AI-powered bioprinting technology, computational design tools, advanced biomaterials, and therapeutic cells.
- CEO / Founder
- Tamer Mohamed
- Team Size
- 100+
- Stage
- Advancing multiple bioprinted tissue therapeutic projects toward clinical trials with Series B funding.
- Total Funding
- $115M
- Latest Round
- Series B
- Key Investors
- ["Dimension","Novo Nordisk","Pallasite Ventures","T1D Fund"]
Technology & Products
Key Products
["Bioprinted tissue therapeutics for metabolic and endocrine diseases"]
Technological Advantage
Full-stack tissue therapeutic platform combining tissue engineering, cell therapy, biomaterials, computer vision, and robotics.
Market & Competition
Target Customers
Patients suffering from serious metabolic and endocrine ailments.
Industry Verticals
["Regenerative medicine","Tissue engineering","Cellular therapies"]
Competitors
["Organovo","Cyfuse Biomedical","Other biotech firms in cellular therapies and biomaterials"]